Market Overview

Morgan Stanley Updates Estimates On Endo Health Solutions

Related ENDP
Watch Out Below, Endo International Investors, Management Is Doubling Down On Weak Assets
Benzinga's Top Downgrades
Tracking Stephen Mandel's Lone Pine Capital Portfolio - Q3 2015 Update (Seeking Alpha)

In a report published Monday, Morgan Stanley analyst Christopher Caponetti reiterated an Equal-Weight rating on Endo Health Solutions (NASDAQ: ENDP).

In the report, Morgan Stanley noted, “Endo's 1.75% convertible notes (due March 2015) and warrants are in-the-money and add roughly 13-15M to Endo's fully-diluted share count. Our new 2014E EPS est. of $3.61 is down 11% vs. our previous $4.05 and near the high end of mgmt's $3.41-$3.65 range (midpt $3.53). Key assumptions: 1. Mylan launches generic Lidoderm in mid-2Q ($49M in royalties from ACT); 2. no generic competition on Voltaren Gel in 2014; 3. 21.6% tax rate; 4. opex down 12% YOY. Delay of Mylan's launch of Gx Lidoderm, more aggressive cost cutting, and lower tax rate are sources of near-term EPS upside.”

Endo Health Solutions closed on Friday at $79.82.

Latest Ratings for ENDP

Nov 2015Mizuho SecuritiesDowngradesBuyNeutral
Nov 2015Standpoint ResearchUpgradesHoldBuy
Nov 2015Deutsche BankMaintainsBuy

View More Analyst Ratings for ENDP
View the Latest Analyst Ratings

Posted-In: Christopher Caponetti Morgan StanleyAnalyst Color Reiteration Analyst Ratings


Related Articles (ENDP)

View Comments and Join the Discussion!

Get Benzinga's Newsletters